Stockscreener 앱 받기
1.60
0.00%
0.00
시간 외 거래:
1.60
전일 마감가:
$1.60
열려 있는:
$1.61
하루 거래량:
239.71K
Relative Volume:
0.48
시가총액:
$31.18M
수익:
-
순이익/손실:
$-40.94M
주가수익비율:
-0.4167
EPS:
-3.84
순현금흐름:
$-22.97M
1주 성능:
-3.61%
1개월 성능:
-36.51%
6개월 성능:
-81.35%
1년 성능:
-82.24%
1일 변동 폭
$1.525
$1.68
1주일 범위
$1.525
$1.7727
52주 변동 폭
$1.525
$20.00
Annovis Bio Inc Stock (ANVS) Company Profile
명칭
Annovis Bio Inc
전화
484-875-3192
주소
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
ANVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.60 | 31.18M | 0 | -40.94M | -22.97M | -3.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2024-10-25 | 업그레이드 | Maxim Group | Hold → Buy |
| 2023-12-29 | 개시 | Canaccord Genuity | Buy |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
Annovis Bio Inc 주식(ANVS)의 최신 뉴스
Annovis Bio stock hits 52-week low at $1.55 amid sharp decline - Investing.com India
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment - GlobeNewswire
Revolutionary Parkinson's Treatment: Annovis Unveils Phase III Data for Multi-Target Drug - StockTitan
LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight - GlobeNewswire Inc.
Atria Wealth Solutions Inc. Purchases Shares of 13,002 Annovis Bio, Inc. (NYSE:ANVS) - Defense World
Annovis Bio stock hits 52-week low at $1.72 amid market challenges - Investing.com Australia
ANVS ALERTLabaton Sucharow Announces the Filing of a Securities Class Action Against Annovis Bio, Inc.; Investors Encouraged to Contact the Firm Before October 18 - ACCESS Newswire
Annovis Bio stock hits 52-week low at $1.72 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN
Annovis Bio stock hits 52-week low at $2.42 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio stock hits 52-week low at $2.42 amid market challenges - Investing.com Australia
Annovis to Host Patients’ Live Forum on February 27, 2025 - GlobeNewswire
Annovis to Host Patients' Live Forum on February 27, 2025 - Quantisnow
Inside Annovis's Groundbreaking Alzheimer's Trial: CEO Opens Direct Dialogue With Patients - StockTitan
Annovis Bio stock hits 52-week low at $2.59 amid sharp decline - MSN
Annovis Bio stock rating cut to hold at D. Boral Capital - MSN
Annovis Bio stock hits 52-week low at $2.59 amid sharp decline By Investing.com - Investing.com South Africa
Annovis Bio CEO to Present at Oppenheimer Healthcare Life Sciences Conference - MSN
Annovis Bio Launches Phase 3 Trial for Alzheimer’s Drug Buntanetap - MSN
Annovis Bio begins pivotal phase 3 Alzheimer's drug trial - MSN
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Annovis Bio Raises $21 Million in Public Offering to Advance Alzheimer’s Research - MSN
Annovis Bio Inc. CEO to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on Pivotal Phase 3 Trial Progress - Nasdaq
Annovis to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - Hamilton Spectator
Annovis Bio (NYSE: ANVS) CEO To Present At Oppenheimer Healthcare Conference - Barchart
Annovis begins treatment of subjects in Alzheimer’s trial - Yahoo Finance
Annovis Bio begins pivotal phase 3 Alzheimer's drug trial By Investing.com - Investing.com Australia
Annovis Bio announces first patients entered Phase 3 study of buntanetap - Yahoo Finance
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease - GlobeNewswire
Annovis Bio stock hits 52-week low at $4.05 amid market challenges - MSN
Annovis Bio sets terms for $21 million public offering - MSN
Annovis Bio completes $21 million stock and warrant offering - MSN
Annovis Bio Enrolls First Patients in Phase 3 Trial of Buntanetap for Early Alzheimer's Disease - Marketscreener.com
Annovis Bio Launches Phase 3 Alzheimer’s Study - TipRanks
Annovis Bio Inc (ANVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.14%
2.83%
자본화:
|
볼륨(24시간):